Cancer Biology & Medicine has been nominated for support in the ‘Action Plan for Excellence of Chinese STM Journals’
To implement “the Opinions on Deepening Reform to Cultivate World-Class Science, Technical and Medical (STM) Journals” issued by Chinese Central Government’s Committee for Deepening Overall Reform and establish world-leading sci-tech journals, an Action Plan for Excellence of Chinese STM Journals(“the Action Plan”) was published jointly by seven administrative departments. The Action Plan will be carried out over a 5-year cycle. In the first year, it will provide nearly 205 million RMB ($29 million USD) funding to support 285 projects which include the development of 280 existing STM journals selected from a total of 837 journal applicants. The scale of this new plan is unprecedented, and therefore it is regarded as a milestone in the development of Chinese STM publishing.
Cancer Biology & Medicine, which is sponsored by the China Anti-cancer Association (CACA) and Tianjin Medical University Cancer Institute and Hospital (TMUCIH), has been selected for support amounting to 5 million RMB over 5 years. Published quarterly, Cancer Biology & Medicine provides innovative and significant information on the biological basis of cancer, the cancer microenvironment, translational cancer research, and all aspects of clinical cancer research. The journal also publishes important perspectives on indigenous types of cancer in China. The editor-in-chief, Professor Xishan Hao, is an academician of the Chinese Academy of Engineering, Vice President of Senologic International Society, Honorary President of China Anti-Cancer Association, and Director of National Clinical Research Center for Cancer (China).
The 2018 Impact Factor of Cancer Biology & Medicine is 4.467; it is located in the Q1 area of the Medicine, Research & Experimental category (ranking 33/136) and Q2 area of the Oncology category (ranking 66/229). In the past three years, more than 52% of authors have come from abroad. Many authors are affiliated to internationally renowned hospitals or cancer research institutes like UT MD Anderson Cancer Center, Harvard Medical School and Dana-Farber Cancer Institute. More than 66% of citations are from authors outside China. Some articles and reviews were cited in high-impact journals such as Nature, New England Journal of Medicine, Lancet, and Cancer Cell. This five-year project will enable Cancer Biology & Medicine to become more competitive and will enable us to maintain our place in the forefront of scholarly publishing by improving the academic quality and international impact of Cancer Biology & Medicine.